Canopy Growth's Stock Faces Grim Future Amid Mediocre Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CGC?
Source: Fool
- Mediocre Financial Performance: Canopy Growth reported net revenue of CA$74.5 million ($54.5 million) for Q3 FY2026, remaining flat year-over-year, while the net loss per share improved from CA$1.11 ($0.81) to CA$0.18 ($0.13), primarily due to a reduction in share-based compensation, failing to indicate operational improvements.
- Declining Free Cash Flow: The company's free cash flow for the quarter was approximately CA$19 million ($13.9 million), down from CA$28.2 million ($20.6 million) in the prior-year quarter, highlighting ongoing financial struggles and a lack of sustainable profitability.
- Limited Regulatory Progress: Although President Trump’s executive order reclassifying cannabis to Schedule III may facilitate banking access and tax deductions for marijuana companies, the continued federal illegality of cannabis sales in the U.S. leaves Canopy Growth's market prospects bleak amid stiff competition.
- Pessimistic Future Outlook: Even if federal legalization occurs, Canopy Growth's previous failures in the Canadian market suggest that success in the U.S. is unlikely, leading analysts to predict that the stock could eventually drop to zero, advising investors to exercise caution.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGC
Wall Street analysts forecast CGC stock price to rise
4 Analyst Rating
1 Buy
2 Hold
1 Sell
Hold
Current: 1.070
Low
1.03
Averages
2.52
High
5.90
Current: 1.070
Low
1.03
Averages
2.52
High
5.90
About CGC
Canopy Growth Corporation is a Canada-based cannabis company. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Lackluster Financial Performance: Canopy Growth reported net revenue of CA$74.5 million ($54.5 million) for Q3 of fiscal 2026, remaining flat year-over-year, indicating a lack of growth momentum, although the net loss per share improved to CA$0.18 ($0.13) from CA$1.11 ($0.81) last year, the overall financial health remains concerning.
- Declining Cash Flow: The company's free cash flow for the quarter was CA$19 million ($13.9 million), down from CA$28.2 million ($20.6 million) in the same period last year, reflecting operational inefficiencies that could hinder future investment capabilities and market confidence.
- Uncertain U.S. Market Outlook: Despite President Trump's executive order reclassifying cannabis to Schedule III, Canopy Growth still faces federal legal restrictions preventing it from operating legally in the U.S. market, limiting its potential for market expansion and profitability.
- Increased Competitive Pressure: Canopy Growth has struggled to find success even after legalization in Canada, and the competition in the U.S. market is expected to intensify, especially post-federal legalization, which could attract more competitors and further squeeze its market share.
See More
- Mediocre Financial Performance: Canopy Growth reported net revenue of CA$74.5 million ($54.5 million) for Q3 FY2026, remaining flat year-over-year, while the net loss per share improved from CA$1.11 ($0.81) to CA$0.18 ($0.13), primarily due to a reduction in share-based compensation, failing to indicate operational improvements.
- Declining Free Cash Flow: The company's free cash flow for the quarter was approximately CA$19 million ($13.9 million), down from CA$28.2 million ($20.6 million) in the prior-year quarter, highlighting ongoing financial struggles and a lack of sustainable profitability.
- Limited Regulatory Progress: Although President Trump’s executive order reclassifying cannabis to Schedule III may facilitate banking access and tax deductions for marijuana companies, the continued federal illegality of cannabis sales in the U.S. leaves Canopy Growth's market prospects bleak amid stiff competition.
- Pessimistic Future Outlook: Even if federal legalization occurs, Canopy Growth's previous failures in the Canadian market suggest that success in the U.S. is unlikely, leading analysts to predict that the stock could eventually drop to zero, advising investors to exercise caution.
See More
- Stock Price Plunge: Canopy Growth's stock has fallen from a peak of $568 in 2018 to its current price of $1.15, resulting in significant paper losses for investors, indicating a dramatic decline in enthusiasm for marijuana investments that necessitates a reassessment of holding strategies.
- Shareholder Dilution Risk: The rapid expansion of Canopy Growth's share count raises concerns about shareholder dilution, further impacting its market appeal and investor confidence, which may lead to increased sell-offs by investors.
- Tax Loss Harvesting: Investors can realize tax losses by selling Canopy Growth shares, allowing them to offset capital gains elsewhere in their portfolios, thereby reducing tax liabilities; this strategy is commonly employed by savvy individual and institutional investors alike.
- Uncertain Future Outlook: While some investors hope for a rebound in Canopy Growth's fortunes, the current financial performance and market conditions heighten the risks associated with holding the stock, prompting investors to carefully consider whether to maintain their positions to avoid further losses.
See More
- Stock Price Plunge: Canopy Growth's stock has fallen from a peak of $568 in 2018 to just over $1 now, leaving investors with significant paper losses and indicating a dramatic decline in enthusiasm for the marijuana sector.
- Profitability Struggles: As a money-losing penny stock, Canopy Growth's ongoing losses and expanding share count raise concerns about shareholder dilution, highlighting major challenges in its business model.
- Tax Loss Harvesting: Investors can realize tax losses by selling Canopy Growth shares, allowing them to offset capital gains elsewhere in their portfolio, showcasing the flexibility of investment strategies to mitigate tax burdens.
- Investment Advice: Canopy Growth was not included in the Motley Fool analyst team's list of the 10 best stocks, reflecting a pessimistic outlook on its future performance, prompting investors to carefully consider whether to hold onto the stock.
See More
- Declining Revenue Trend: Altria's total net revenue fell by 3% in 2025 to $23.3 billion, indicating a weakening reliance on the traditional cigarette market, although the company continues to maintain high margins and strong cash flow.
- Transformation Strategy: The company is implementing its 'Moving Beyond Smoking' strategy, aiming to become a smoke-free product supplier by 2030, despite facing significant setbacks in electronic cigarettes and oral tobacco products due to a patent infringement lawsuit, highlighting the challenges of this transition.
- Dividend Appeal: Altria is dubbed a 'Dividend King' with a 56-year streak of dividend increases, recently raising its quarterly dividend to $4.24 per share, yielding 6.3%, which provides an attractive option for income-seeking investors.
- Market Uncertainty: While Altria faces challenges in its transformation process, it continues to attract investors through strong dividend returns; however, the future market environment and the progress of its transition remain uncertain.
See More
- Revenue Decline: Altria's total net revenue fell by 3% in 2025 to under $23.3 billion, indicating a weakening reliance on the traditional cigarette market, although it maintains a high gross margin of 75.83%.
- Dividend King Status: In mid-2025, Altria raised its quarterly dividend by 4% to $4.24 per share, yielding 6.3%, which keeps it competitive in the high-yield sector and attracts income-focused investors.
- Transition Challenges: While Altria aims to become a smoke-free product provider by 2030, its recent patent infringement loss highlights uncertainties in its transition, with smokeable products still accounting for 88% of net revenue.
- Strong Cash Flow: Last year, Altria generated over $9 billion in free cash flow, marking the second-highest level in five years, ensuring the company can continue its dividend payments and fund future investments.
See More









